The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Molecular Pathways Underlying Cardiac Remodeling During Pathophysiological Stimulation
Open accessAbstract
Cardiac remodeling involves molecular, cellular, and interstitial changes that manifest clinically as changes in size, shape, and function of the heart after injury or stress stimulation.1 Although the term cardiac remodeling was initially coined to describe the prominent changes that occur after myocardial infarction,2,3 it is clear that similar processes transpire after other types of injury such as with pressure overload (aortic valve stenosis, hypertension), inflammatory disease (myocarditis), idiopathic dilated cardiomyopathy, and volume overload (valvular regurgitation). Although the causes of these diseases are different, they share molecular, biochemical, and cellular events to collectively change the shape of the myocardium. Cardiac hypertrophy is a common type of cardiac remodeling that occurs when the heart experiences elevated workload. The heart and individual myocytes enlarge as a means of reducing ventricular wall and septal stress when faced with increased workload or injury. Cardiac hypertrophy is classified as “physiological” when it occurs in healthy individuals after exercise or pregnancy and is not associated with cardiac damage. In contrast, hypertrophy that results from pressure or volume overload or after myocardial infarction is usually referred to as “pathological.” This name may be misleading, however, because pathological hypertrophy may also involve a compensatory and adaptive phase that tends to reduce wall stress and maintain output, although ultimately these positive aspects are lost and ventricular function declines, often leading to heart failure. In addition to ventricular remodeling, pathological cardiac hypertrophy involves cellular and molecular remodeling such as myocyte growth without significant proliferation, reexpression of fetal genes, alterations in the expression of proteins involved in excitation-contraction coupling, and changes in the energetic and metabolic state of the myocyte. These cellular and molecular changes within the myocyte are accompanied by changes in the extracellular matrix (ECM) and by myocyte death caused by necrosis or apoptosis. As …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of inositol 1,4,5-trisphosphate-induced Ca2+ release by cytosolic Ca2+
Bootman, M. D., Missiaen, L., Parys, J. B., De Smedt, H., & Casteels, R. (1995) · Biochemical Journal · doi:10.1042/bj3060445 · Cited by 5,120
Pfeffer, M. A., & Braunwald, E. (1990) · Circulation · doi:10.1161/01.cir.81.4.1161 · Cited by 2,877
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Self-citationHaberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Cohn, J. N., Ferrari, R., & Sharpe, N. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00630-0 · Cited by 2,161
Organization and regulation of mitogen-activated protein kinase signaling pathways
Garrington, T. P., & Johnson, G. L. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80028-3 · Cited by 1,275
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228
Spinale, F. G. (2007) · Physiological Reviews · doi:10.1152/physrev.00012.2007 · Cited by 1,120
Sundaresan, N. R., Gupta, M., Kim, G., Rajamohan, S. B., Isbatan, A., & Gupta, M. P. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39162 · Cited by 995
Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy
Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., & Olson, E. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00861-9 · Cited by 973
Cited by
Horckmans, M., Ring, L., Duchene, J., Santovito, D., Schloss, M. J., Drechsler, M., Weber, C., Soehnlein, O., & Steffens, S. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw002 · Cited by 727
Frantz, S., Hundertmark, M. J., Schulz-Menger, J., Bengel, F. M., & Bauersachs, J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac223 · Cited by 606
Pathophysiology of Heart Failure
Tanai, E., & Frantz, S. (2015) · Comprehensive Physiology · doi:10.1002/cphy.c140055 · Cited by 552
Regulation of Signal Transduction by Reactive Oxygen Species in the Cardiovascular System
Brown, D. I., & Griendling, K. K. (2015) · Circulation Research · doi:10.1161/circresaha.116.303584 · Cited by 496
The N 6 -Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy
Dorn, L. E., Lasman, L., Chen, J., Xu, X., Hund, T. J., Medvedovic, M., Hanna, J. H., van Berlo, J. H., & Accornero, F. (2019) · Circulation · doi:10.1161/circulationaha.118.036146 · Cited by 466
Pathophysiology of heart failure
Schwinger, R. H. G. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-302 · Cited by 428
Left Ventricular Structural Remodeling in Health and Disease
Gaasch, W. H., & Zile, M. R. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.07.022 · Cited by 426
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy
Cao, D. J., Wang, Z. V., Battiprolu, P. K., Jiang, N., Morales, C. R., Kong, Y., Rothermel, B. A., Gillette, T. G., & Hill, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015081108 · Cited by 405
Myocardial Extracellular Matrix: An Ever-Changing and Diverse Entity
Rienks, M., Papageorgiou, A.-P., Frangogiannis, N. G., & Heymans, S. (2014) · Circulation Research · doi:10.1161/circresaha.114.302533 · Cited by 366
Cuspidi, C., Sala, C., Negri, F., Mancia, G., Morganti, A., & on behalf of the Italian Society of Hypertension (2012) · Journal of Human Hypertension · doi:10.1038/jhh.2011.104 · Cited by 333
Role of m6A RNA methylation in cardiovascular disease (Review)
Qin, Y., Li, L., Luo, E., Hou, J., Yan, G., Wang, D., Qiao, Y., & Tang, C. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4746 · Cited by 328
Gladka, M. M., Molenaar, B., de Ruiter, H., van der Elst, S., Tsui, H., Versteeg, D., Lacraz, G. P. A., Huibers, M. M. H., van Oudenaarden, A., & van Rooij, E. (2018) · Circulation · doi:10.1161/circulationaha.117.030742 · Cited by 310
The fibrosis-cell death axis in heart failure
Piek, A., de Boer, R. A., & Silljé, H. H. W. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9536-9 · Cited by 301
The vortex—an early predictor of cardiovascular outcome?
Pedrizzetti, G., La Canna, G., Alfieri, O., & Tonti, G. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.75 · Cited by 284
ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy
Gallo, S., Vitacolonna, A., Bonzano, A., Comoglio, P., & Crepaldi, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092164 · Cited by 264
Gorski, P. A., Ceholski, D. K., & Hajjar, R. J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.005 · Cited by 213
Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy
Zaglia, T., Milan, G., Ruhs, A., Franzoso, M., Bertaggia, E., Pianca, N., Carpi, A., Carullo, P., Pesce, P., Sacerdoti, D., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66339 · Cited by 147
Hypertensive Disorders of Pregnancy and Offspring Cardiac Structure and Function in Adolescence
Timpka, S., Macdonald‐Wallis, C., Hughes, A. D., Chaturvedi, N., Franks, P. W., Lawlor, D. A., & Fraser, A. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003906 · Cited by 106
“12,13 The increase in number of myocytes in the human myocardium plateaus during early life, and subsequent cardiac growth is mostly mediated through hypertrophy of previously formed myocytes.”
Sung, M. M., Das, S. K., Levasseur, J., Byrne, N. J., Fung, D., Kim, T. T., Masson, G., Boisvenue, J., Soltys, C.-L., Oudit, G. Y., et al. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.001677 · Cited by 102
Ulla, A., Mohamed, M. K., Sikder, B., Rahman, A. T., Sumi, F. A., Hossain, M., Reza, H. M., Rahman, G. M. S., & Alam, M. A. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0136-7 · Cited by 80
“Cardiac hypertrophy is a typical type of cardiac remodeling [2], where not only the crucial cardiac cell myocyte, but also other components like fibroblasts, collagens, coronary vasculature, interstitium are involved in remodeling process which finally causes ischemia, apoptosis and cell necrosis [3].”
BackgroundChen, J. J., Wu, P.-T., Middlekauff, H. R., & Nguyen, K.-L. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00646.2016 · Cited by 71
Rhee, A. J., & Lavine, K. J. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034412 · Cited by 46
Li, J., Li, C., Zhang, D., Shi, D., Qi, M., Feng, J., Yuan, T., Xu, X., Liang, D., Xu, L., et al. (2014) · Nature Communications · doi:10.1038/ncomms6177 · Cited by 46
The Functional Consequences of Sodium Channel NaV1.8 in Human Left Ventricular Hypertrophy
Ahmad, S., Tirilomis, P., Pabel, S., Dybkova, N., Hartmann, N., Molina, C. E., Tirilomis, T., Kutschka, I., Frey, N., Maier, L. S., et al. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12378 · Cited by 41
García-Niño, W. R., Zúñiga-Muñoz, A. M., & Maldonado-Macías, X. P. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178715 · Cited by 1
Metadata
- Authors
- Kehat, I., & Molkentin, J. D.
- Venue
- Circulation
- Published
- 2010-12-21
- Volume
- 122
- Issue
- 25
- Pages
- 2727-2735
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2089365655
- Cited by
- 592
- References
- 80
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.